Removal of gp160 induced bio-hazards for a safe AIDS vaccine candidate.
In the first AIDS vaccine trial, immunizing preparations were based on HIV-1 Env protein (gp160). Immunogenic properties of gp160 which trigger both a humoral and cellular immune response have since justified its use in various vaccine programs, both past and present. Many reports however have underlined deleterious effects on the immune system--anti-HIV-1 enhanced antibodies, anti-CD4 autoantibodies, and inhibition of T cell activation by HIV-1--particularly associated with the Env protein. The present study shows that gp160 presented in a biologically inactivated but immunogenic form, as used in our trial, could avoid these complications. Bio-hazards associated with gp160 which indeed could be removed by appropriate treatment of the native protein, should be taken into consideration in AIDS vaccine programs.
Picard
O
O
Hôpital St Antoine (Service du Prof Inbert), Paris.
Bernard
J
J
Lachgar
A
A
Fall
L
L
Carlotti
M
M
Achour
A
A
Carelli
C
C
Salaun
J J
JJ
Mbika
J P
JP
Lurhuma
Z
Z
D016915:AIDS Vaccines / Q000276:immunology / Q000494:pharmacology*; D001323:Autoantibodies / Q000187:drug effects; D015704:CD4 Antigens / Q000276:immunology; D015686:Gene Products, env / Q000009:adverse effects* / Q000276:immunology; D019302:HIV Envelope Protein gp160; D015497:HIV-1 / Q000737:chemistry*; D006801:Humans; D007107:Immune System / Q000187:drug effects*; D008213:Lymphocyte Activation / Q000187:drug effects; D011498:Protein Precursors / Q000009:adverse effects* / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D015164:Vaccines, Inactivated / Q000276:immunology / Q000494:pharmacology; D014759:Viral Envelope Proteins / Q000009:adverse effects* / Q000276:immunology
D016915:AIDS Vaccines; D001323:Autoantibodies; D015704:CD4 Antigens; D015686:Gene Products, env; D019302:HIV Envelope Protein gp160; D011498:Protein Precursors; D015164:Vaccines, Inactivated; D014759:Viral Envelope Proteins